Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Adverum Biotechnologies Inc (ADVM)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Adverum Biotechn's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
9.190 -0.200    -2.13%
26/04 - Closed. Currency in USD ( Disclaimer )
After Hours
9.640
+0.450
+4.897%
21:50:20 - Real-time Data
  • Volume: 743,739
  • Bid/Ask: 9.190 / 9.800
  • Day's Range: 9.110 - 10.100
Type:  Equity
Market:  United States
Adverum Biotechn 9.190 -0.200 -2.13%

Adverum Biotechn Company Profile

 
Read the Adverum Biotechnologies Inc company profile to learn more about the business and the management team. View Adverum Biotechnologies Inc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

123

Equity Type

ORD

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Contact Information

Address 100 Cardinal Way
Redwood City, 94063
United States
Phone 650 656 9323
Fax 650 649 1995

Top Executives

Name Age Since Title
C. Patrick Machado 59 2017 Independent Chairman
Dawn A. Svoronos 70 2020 Independent Director
James Paul Scopa 64 2019 Independent Director
Laurent Fischer 59 2020 President, CEO & Director
Szilard Kiss - - Scientific Advisory Board Member
Mark L. Lupher 52 2019 Independent Director
Soo J. Hong 51 2022 Independent Director
Reed Vaughn Tuckson 72 2021 Independent Director
Scott M. Whitcup 64 2020 Independent Director
David S. Boyer - - Scientific Advisory Board Member
Arshad M. Khanani - - Scientific Advisory Board Member
Charles C. Wykoff - - Scientific Advisory Board Member
Rabia Gurses Ozden 55 2022 Independent Director
Jeffrey S. Heier 62 - Scientific Advisory Board Member
C. David Nicholson 68 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ADVM Price Commentary

Write your thoughts about Adverum Biotechnologies Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email